Although prostate cancer (PCa) is one of the most common tumors in European males, the
only minimally invasive diagnostic tool in PCa setup is the determination of PSA in serum …

Background Despite most metastatic castration-resistant prostate cancer (mCRPC) patients
benefit from abiraterone acetate plus prednisone 5 mg bid (AA+ P), resistance eventually …

Background Currently, several therapies are available for metastatic castration-resistant
prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first …

Abstract Background In a Phase 2 clinical trial, we aimed to determine the lutetium-177
[177Lu]-PSMA-617 activity and the clinical utility of levels of plasma androgen receptor (AR) …

Background Plasma androgen receptor (AR) copy number status has been identified as a
potential biomarker of response in patients with metastatic castration-resistant prostate …

Prostate cancer is the second most common male malignancy, with a highly variable clinical
presentation and outcome. Therefore, diagnosis, prognostication, and management remain …

Purpose: Although cell-free DNA (cfDNA) testing is expected to drive cancer precision
medicine, little is known about the significance of detecting low-frequency variants in …

PURPOSE It has been suggested that androgen receptor copy number gain (AR gain)
detected in cell-free DNA (cfDNA) can predict treatment response to androgen receptor …

Hormonal therapies including androgen deprivation therapy and androgen receptor (AR)
pathway inhibitors such as abiraterone and enzalutamide have been widely used to treat …

Liquid biopsy is emerging as an intriguing tool in clinical disease detection and monitoring.
Compared to a standard tissue biopsy, performing a liquid biopsy incurs minimal …